首页    期刊浏览 2024年11月30日 星期六
登录注册

文章基本信息

  • 标题:Oncostatin M-induced astrocytic tissue inhibitor of metalloproteinases-1 drives remyelination
  • 本地全文:下载
  • 作者:Evelien Houben ; Kris Janssens ; Doryssa Hermans
  • 期刊名称:Proceedings of the National Academy of Sciences
  • 印刷版ISSN:0027-8424
  • 电子版ISSN:1091-6490
  • 出版年度:2020
  • 卷号:117
  • 期号:9
  • 页码:5028-5038
  • DOI:10.1073/pnas.1912910117
  • 出版社:The National Academy of Sciences of the United States of America
  • 摘要:The brain’s endogenous capacity to restore damaged myelin deteriorates during the course of demyelinating disorders. Currently, no treatment options are available to establish remyelination. Chronic demyelination leads to damaged axons and irreversible destruction of the central nervous system (CNS). We identified two promising therapeutic candidates which enhance remyelination: oncostatin M (OSM), a member of the interleukin-6 family, and downstream mediator tissue inhibitor of metalloproteinases-1 (TIMP-1). While remyelination was completely abrogated in OSMRβ knockout (KO) mice, OSM overexpression in the chronically demyelinated CNS established remyelination. Astrocytic TIMP-1 was demonstrated to play a pivotal role in OSM-mediated remyelination. Astrocyte-derived TIMP-1 drove differentiation of oligodendrocyte precursor cells into mature oligodendrocytes in vitro. In vivo, TIMP-1 deficiency completely abolished spontaneous remyelination, phenocopying OSMRβ KO mice. Finally, TIMP-1 was expressed by human astrocytes in demyelinated multiple sclerosis lesions, confirming the human value of our findings. Taken together, OSM and its downstream mediator TIMP-1 have the therapeutic potential to boost remyelination in demyelinating disorders.
  • 关键词:oncostatin M ; remyelination ; oligodendrocyte precursor cells ; astrocytes ; tissue inhibitor of metalloproteinases-1
国家哲学社会科学文献中心版权所有